Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 INCB099280 study in advanced cutaneous squamous cell carcinoma
NL-OMON60549Phase 2Withdrawn
- Sponsor
- Incyte
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of incb099280 in cutaneous squamous cell carcinoma (cSCC) (3 arms), sponsored by Incyte. Primary endpoints: Objective response rate, Incidence of treatment-emergent adverse events and 1 more. Planned start Jul 2023; status: withdrawn.
02
Drugs
incb099280
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NL-OMON60549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60549.